Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen

Urology

Volumn 47, Issue 2, 1996, Pages 212-217

  Labrie, Fernand ^a,b   Candas, Bernard ^a   Cusan, Leonello ^a   Gomez, José Luis ^a   Diamond, Pierre ^a   Suburu, Raul ^a   Lemay, Martin ^a  

^a Lab of Molecular Endocrinology   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CANCER LOCALIZATION; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSIS; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSURETHRAL RESECTION;

EID: 0029867037     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80419-1     Document Type: Article

References (37)

1. Wingo PA, Tong T, and Bolden S: Cancer statistics, 1995. CA Cancer J Clin 45: 8-30, 1995.
2. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, et al: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5: 267-275, 1982.
3. Labrie F, Dupont A, and Bélanger A: Complete androgen blockade for the treatment of prostate cancer, in de Vita VT, Hellman S, and Rosenberg SA (Eds): Important Advances in Oncology. Philadelphia, JB Lippincott, 1985, pp 193-217.
4. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
5. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, and Depauw M: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center. Urology 42: 119-129, 1993.
6. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Da Silva FC, Chisholm G, Crawford ED, Debruyne FM, et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multi-national double-blind randomized trial. J Urol 149: 77-83, 1993.
7. Labrie F: Endocrine therapy of prostate cancer: optimal form and timing. J Clin Endocrinol Metab 80: 1066-1071, 1995.
8. Jewett HJ, Bridge RW, Gray GF Jr, and Shelley WM: The palpable nodule of prostatic cancer. Results 15 years after radical excision. JAMA 203: 403-406, 1968.
9. Lee F, Torp-Pedersen ST, and Siders DB: Use of transrectal ultrasound in diagnosis, guided biopsy, staging, and screening of prostate cancer. Urology 33 (suppl): 7-12,1989.
10. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, Igel TC, and Kidd DD: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate-specific antigen. J Urol 143: 1146-1154, 1990.
11. Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez JL, and Emond J: Serum prostatic specific antigen as prescreening test for prostate cancer. J Urol 147: 846-852, 1992.
12. Labrie F, Dupont A, Suburu R, Cusan L, Gomez JL, Koutsilieris M, Diamond P, Emond J, Lemay M, and Candas B: Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostatic-specific antigen. Clin Invest Med 16: 425-439, 1993.
13. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, and Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161, 1991.
14. Mettlin C: Early detection of prostate cancer following repeated examinations by multiple modalities: results of the American Cancer Society National Prostate Cancer Detection Project. Clin Invest Med 16: 440-447, 1993.
15. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Panser LA, Girman CJ, and Lieber MM: The establishment of age-specific reference ranges for prostate-specific antigen. J Urol 149: 510A, 1993.
16. Gann PH, Hennekens CH, and Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273: 289-294, 1995.
17. Aus G, Bergdahl S, Hugosson J, Lodding P, and Norlén L: Influence of benign prostatic hyperplasia, testosterone and age on serum levels of prostate specific antigen. Scand J Urol Nephrol 28: 379-384, 1994.
18. Lee F, Littrup PJ, Loft-Christensen L, Kelly BS Jr, McHugh TA, Siders DB, Mitchell AE, and Newby JE: Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer. Cancer 70 (suppl): 211-220, 1992.
19. Littrup PJ, Williams CR, Egglin TK, and Kane RA: Determination of prostate volume with transrectal US for cancer screening. Part II. Accuracy of in vitro and in vivo techniques. Radiology 179: 49-53, 1991.
20. Hodge KK, McNeal JE, Terris MF, and Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-75, 1989.
21. Murphy GP, Natarajan N, Pontes JE, Schmitz RL, Smart CR, Schmidt JD, and Mettlin C: The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 127: 928-934, 1982.
22. Schmidt JD, Mettlin CJ, Natarajan N, Peace BB, Beart RW Jr, Winchester DP, and Murphy GP: Trends in patterns of care for prostatic cancer, 1974-1983: results of surveys by the American College of Surgeons. J Urol 136: 416-421, 1986.
23. Hulka BS: Cancer screening. Degrees of proof and practical application. Cancer 62: 1776-1780, 1988.
24. Narod S, Dupont A, Cusan L, Diamond P, Gomez JL, Suburu RE, and Labrie F: The impact of family history on early detection of prostate cancer. Nat Med 1: 99-101, 1995.
25. Catalona WJ: Management of cancer of the prostate. N Engl J Med 331: 996-1004, 1994.
26. Epstein JI, Walsh PC, Carmichael M, and Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tie) prostate cancer. JAMA 271: 368-374, 1994.
27. Aihara M, Wheeler TM, Ohori M, and Scardino PT: Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 43: 60-66, 1994.
28. McNeal JE: Editorial comments. Urology 43: 66-67, 1994.
29. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, and Krusemo UB: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267: 2191-2196, 1992.
30. Adolfsson J, CarstensenJ, and Lowhagen T: Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 69: 183-187, 1992.
31. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, Chisholm GD, Moskovitz B, Livne PM, and Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242-248, 1994.
32. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, and Candas B: Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44: 29-37, 1994.
33. Labrie F, Cusan L, Gomez JL, Diamond P, and Candas B: Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J Clin Endocrinol Metab 80: 2002-2013, 1995.
34. Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, LeMay M, Tetu B, et al: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16: 499-509, 1993.
35. Littrup PJ, Kane RA, Mettlin CJ, Murphy GP, Lee F, Toi A, Badalament R, and Babaian R: Cost-effective prostate-cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 74: 3146-3158, 1994.
36. Aus G, Hugosson J, and Norlén L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154: 460-465, 1995.
37. Labrie F: Intracrinology and cancer therapy. Sci Watch 5: 3-8, 1994.